Noticias y Actividades de Hepion Pharmaceuticals

Hepion Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización HEPA (US).

Fusión, adquisición y financiación con participación de Hepion Pharmaceuticals.

• Hepion Pharmaceuticals and Pharma Two B have announced they will merge  (publicado el 8 de agosto de 2024)..

Ver el organigrama con sus 5 ejecutivos principales

Biografías más buscadas en Hepion Pharmaceuticals

• Timothy Block, Director
• Kaouthar Lbiati, Director
• John Brancaccio, Chairman of the Board

Recientes movimientos de ejecutivos en Hepion Pharmaceuticals

• John Cavan, Chief Financial Officer and Interim Chief Executive Officer, ha dejado la empresa  (noticia publicada el 8 de agosto de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Hepion Pharmaceuticals.

Hepion Pharmaceuticals tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado el 12 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Paul Meister - Chairman of the Board en Amneal Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Hepion Pharmaceuticals

• Hepion Pharmaceuticals Announces Reverse Stock Split – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces $9.0 Million Public Offering – Hepion Pharmaceuticals
• Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. – Hepion Pharmaceuticals
• Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B – Hepion Pharmaceuticals
• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell – Hepion Pharmaceuticals
• View more press releases Close

Redes sociales sobre Hepion Pharmaceuticals

• Hepion Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Hepion Pharmaceuticals en LinkedIn, Twitter y YouTube